Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)

NCT04155125 is registered in ClinicalTrials.gov with PT Kalbe Genexine Biologics as lead sponsor.

NCT NCT04155125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)
Lead sponsor
PT Kalbe Genexine Biologics
Phase
Phase 3
Overall status
Completed
Start date
July 2, 2020
Completion date
June 30, 2023
Enrollment
391 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia associated with chronic kidney disease